{"id":14,"date":"2024-11-27T18:37:45","date_gmt":"2024-11-27T18:37:45","guid":{"rendered":"https:\/\/www.adarx.com\/?page_id=14"},"modified":"2026-09-04T14:47:46","modified_gmt":"2026-09-04T21:47:46","slug":"science-overview","status":"publish","type":"page","link":"https:\/\/www.adarx.com\/dev\/science\/science-overview\/","title":{"rendered":"Science Overview"},"content":{"rendered":"\n<h2 class=\"wp-block-heading h2-alt\">Overview<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">RNA Therapeutics<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In 2006, Dr. Andrew Fire and Dr. Craig Mello received the Nobel Prize in Physiology or Medicine for their groundbreaking discovery of RNA interference (RNAi) \u2013 a natural gene-silencing mechanism triggered by double-stranded RNA. Since then, RNA-based technologies have demonstrated success in treating diseases where traditional therapies have limitations, taking advantage of the body\u2019s own cellular processes to control protein expression at its source.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Our Unique Approach at ADARx<\/h3>\n\n\n\n<p class=\"large-marge wp-block-paragraph\">At ADARx, we have developed proprietary, next-generation siRNA technologies that are collectively designed to optimize our siRNA sequences and delivery to tissues both in the liver and outside the liver. Using these technologies, we seek to develop novel therapeutics prioritizing chronic diseases where deep, durable target suppression can enable meaningful clinical benefit for patients with significant unmet need.<\/p>\n\n\n\n<div id=\"science-band-01\" class=\"figure alignfull\" style=\"background-color:#DFE5E3;\"><div class=\"safezoneB\"><div class=\"bandText2\">\n\n\n\n<h3 class=\"wp-block-heading\"><strong><strong>Our approach centers on three core pillars:<\/strong><\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list no-marge\">\n<li><strong>Sequence engineering:<\/strong> Leverage our proprietary computational platform to generate unique insights from oligonucleotide-enzyme interactions, with the goal of consistently driving differentiated potency and durability for our therapeutic candidates.<\/li>\n\n\n\n<li><strong>Broad delivery:<\/strong> Unlock the potential of siRNA therapeutic candidates beyond the liver via targeted delivery to extrahepatic tissues, such as adipose, neurons, microglia, skeletal muscle, cardiac muscle and ocular tissues, thereby broadening the landscape of diseases we can seek to address.<\/li>\n\n\n\n<li><strong>Strategic indication selection:<\/strong> Prioritize diseases, with a focus on chronic conditions, where our technologies have the potential to drive deep, or even near complete, and durable target suppression to enable meaningful clinical benefit for patients with significant unmet need.<\/li>\n<\/ul>\n\n\n\n<\/div><\/div><\/div>\n\n\n\n<p class=\"large-marge wp-block-paragraph\">By combining deep siRNA expertise, an unwavering commitment to innovation, and a patient-centric focus, ADARx is advancing programs designed to selectively silence the target at its source and overcome the limitations of existing siRNA therapeutics to realize the full potential of siRNA therapeutics.<\/p>\n\n\n\n<p class=\"inline-nav wp-block-paragraph\">\u203a <a href=\"https:\/\/www.adarx.com\/dev\/science\/technology\/#rnai\">RNAi<\/a> \u203a <a href=\"https:\/\/www.adarx.com\/dev\/science\/technology\/#delivery\">Delivery<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Overview RNA Therapeutics In 2006, Dr. Andrew Fire and Dr. Craig Mello received the Nobel Prize in Physiology or Medicine for their groundbreaking discovery of RNA interference (RNAi) \u2013 a natural gene-silencing mechanism triggered by double-stranded RNA. Since then, RNA-based technologies have demonstrated success in treating diseases where traditional therapies have limitations, taking advantage of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":12,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-14","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Science Overview - ADARx Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Science Overview - ADARx Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Overview RNA Therapeutics In 2006, Dr. Andrew Fire and Dr. Craig Mello received the Nobel Prize in Physiology or Medicine for their groundbreaking discovery of RNA interference (RNAi) \u2013 a natural gene-silencing mechanism triggered by double-stranded RNA. Since then, RNA-based technologies have demonstrated success in treating diseases where traditional therapies have limitations, taking advantage of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adarx.com\/dev\/science\/science-overview\/\" \/>\n<meta property=\"og:site_name\" content=\"ADARx Pharmaceuticals\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T21:47:46+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/science\\\/science-overview\\\/\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/science\\\/science-overview\\\/\",\"name\":\"Science Overview - ADARx Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\"},\"datePublished\":\"2024-11-27T18:37:45+00:00\",\"dateModified\":\"2026-09-04T21:47:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/science\\\/science-overview\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.adarx.com\\\/dev\\\/science\\\/science-overview\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/science\\\/science-overview\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Science Overview\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\",\"name\":\"ADARx Pharmaceuticals\",\"description\":\"Providing hope for patients with intractable disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Science Overview - ADARx Pharmaceuticals","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Science Overview - ADARx Pharmaceuticals","og_description":"Overview RNA Therapeutics In 2006, Dr. Andrew Fire and Dr. Craig Mello received the Nobel Prize in Physiology or Medicine for their groundbreaking discovery of RNA interference (RNAi) \u2013 a natural gene-silencing mechanism triggered by double-stranded RNA. Since then, RNA-based technologies have demonstrated success in treating diseases where traditional therapies have limitations, taking advantage of [&hellip;]","og_url":"https:\/\/www.adarx.com\/dev\/science\/science-overview\/","og_site_name":"ADARx Pharmaceuticals","article_modified_time":"2026-09-04T21:47:46+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adarx.com\/dev\/science\/science-overview\/","url":"https:\/\/www.adarx.com\/dev\/science\/science-overview\/","name":"Science Overview - ADARx Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/#website"},"datePublished":"2024-11-27T18:37:45+00:00","dateModified":"2026-09-04T21:47:46+00:00","breadcrumb":{"@id":"https:\/\/www.adarx.com\/dev\/science\/science-overview\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adarx.com\/dev\/science\/science-overview\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.adarx.com\/dev\/science\/science-overview\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.adarx.com\/dev\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/www.adarx.com\/dev\/science\/"},{"@type":"ListItem","position":3,"name":"Science Overview"}]},{"@type":"WebSite","@id":"https:\/\/www.adarx.com\/dev\/#website","url":"https:\/\/www.adarx.com\/dev\/","name":"ADARx Pharmaceuticals","description":"Providing hope for patients with intractable disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adarx.com\/dev\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/14","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/comments?post=14"}],"version-history":[{"count":35,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/14\/revisions"}],"predecessor-version":[{"id":1014,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/14\/revisions\/1014"}],"up":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/12"}],"wp:attachment":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/media?parent=14"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}